UPMC led global trial fast tracks testing of hydroxychloroquine, other COVID-19 therapies
Excerpt from the article:
PITTSBURGH, April 9, 2020 – A novel clinical trial developed by researchers at the University of Pittsburgh School of Medicine launched today at UPMC to address one of the most important debates during the COVID-19 pandemic: How should doctors decide between quickly adopting new therapies, such as the anti-malarial drug hydroxychloroquine, and waiting until they are tested in longer clinical trials?
“The solution is to find an optimal tradeoff between doing something now, such as prescribing a drug off-label, or waiting until traditional clinical trials are complete,” said Derek Angus, M.D., M.P.H., professor and chair, Department of Critical Care Medicine at Pitt and UPMC. “We’ve developed a way to do that with an adaptive clinical trial model that relies on a type of artificial intelligence known as reinforcement learning to identify the best, evidence-backed therapy for COVID-19 much faster than using the traditional scientific approach.”
Click the button below to read the entire article:
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?